Ultragenyx submits European gene therapy application for MPS IIIA

Ultragenyx has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for its investigational gene therapy, rebisufligene etisparvovec, intended for the treatment of MPS IIIA (Sanfilippo Syndrome Type A).